Sarissa Capital Management »

Neurocrine Biosciences shares owned by Sarissa Capital Management

Quarter-by-quarter ownership of Neurocrine Biosciences (NBIX) shares owned by Sarissa Capital Management from 13F filings

Historical chart of Sarissa Capital Management investment in Neurocrine Biosciences

Tip: Access up to 7 years of quarterly data

All positions including Neurocrine Biosciences held by Sarissa Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Neurocrine Biosciences by Sarissa Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $62M 470k 131.76
2023-09-30 $41M 366k 112.50
2023-06-30 $22M 231k 94.30

More positions owned by Sarissa Capital Management

Ironwood Pharmaceuticals Com Cl A (IRWD)
Biogen Idec (BIIB)
Innoviva (INVA)
Gilead Sciences (GILD)
Neurocrine Biosciences (NBIX)
Amarin Corp Spons Adr New (AMRN)
BioCryst Pharmaceuticals (BCRX)
Vor Biopharma (VOR)
Regulus Therapeutics (RGLS)

View all positions for Sarissa Capital Management

Top funds holding Neurocrine Biosciences

Vanguard Group
Bellevue Group
Jpmorgan Chase & Co
Henderson Group
T. Rowe Price Associates
Point72 Asset Management
Dodge & Cox
DSM Capital Partners
Wellington Management Company
Brown Advisory Holdings Incorporated
Bank of New York Mellon
Deerfield Management Company
Franklin Resources
Jacobs Levy Equity Management
AQR Capital Management

View all funds holding Neurocrine Biosciences